← Back to Search

S95011 concentrate for solution for infusion for Sjögren's Syndrome

Phase 2
Waitlist Available
Research Sponsored by Institut de Recherches Internationales Servier
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at baseline, week 4 and week 13

Summary

This trial is testing if giving a medication called S95011 can help reduce symptoms in people with primary Sjögren's syndrome, a condition where the immune system attacks moisture-producing glands.

Eligible Conditions
  • Sjögren's Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at baseline, week 4 and week 13
This trial's timeline: 3 weeks for screening, Varies for treatment, and at baseline, week 4 and week 13 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in ESSDAI Total Score
Secondary study objectives
ESSDAI Score by Domain and Total Score
ESSPRI Score by Symptom and Total Score
Fatigue (MFI)
+4 more

Side effects data

From 2023 Phase 2 trial • 48 Patients • NCT04605978
16%
COVID-19
13%
Lymphopenia
6%
Parotitis
6%
Oral Herpes
6%
Purpura
6%
Hypertension
3%
Amaurosis fugax
3%
Herpes zoster
3%
Cystitis
3%
Neutropenia
3%
Infusion related reaction
3%
Nasopharyngitis
3%
Constipation
3%
Arthralgia
3%
Myalgia
100%
80%
60%
40%
20%
0%
Study treatment Arm
S95011 Placebo Concentrate for Solution for Infusion
S95011 Concentrate for Solution for Infusion

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: S95011 concentrate for solution for infusionExperimental Treatment1 Intervention
S95011 is administrated by one IV infusion every 2 weeks for the first month and then every 3 weeks.
Group II: S95011 Placebo concentrate for solution for infusionPlacebo Group1 Intervention
S95011 placebo is administrated by one IV infusion every 2 weeks for the first month and then every 3 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
S95011 concentrate for solution for infusion
2021
Completed Phase 2
~50

Find a Location

Who is running the clinical trial?

Institut de Recherches Internationales ServierLead Sponsor
90 Previous Clinical Trials
67,106 Total Patients Enrolled
ADIR, a Servier Group companyIndustry Sponsor
32 Previous Clinical Trials
4,286 Total Patients Enrolled
~11 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top